# Phase 2 completion audit and implementation-gate handoff

**Audit date:** 2026-08-21
**Assessed baseline:** `phase-1-experimental^{}` = `d77a8320e6751a2deb2daf14cf1ac5d6b00cb989`
**Overall determination:** Phase 2 documentation, finding synthesis, target-policy decisions, and Phase 3 preparation deliverables are complete. The broader Phase 2 assurance assessment remains In review, and the Phase 2 **implementation authorization gate is deliberately not complete**: coverage rows still require specialist, current-environment, and delivery evidence under the program owner's standing instruction.

## Audit standard

This audit distinguishes completed Phase 2 evidence/planning artifacts from proof that the product is safe or ready to deploy. An individual assessment deliverable is complete when its evidence, limits, owner decision, and next action are recorded against the fixed baseline. Broad coverage rows stay In review until their required specialist or current-environment evidence exists. An implementation gate can close only when the explicit requirements in the [Phase 2 exit gate](phase-2-exit-gate.md) are satisfied and the program owner directs closure. No current record claims production deployment, legal compliance, certification, or completed remediation.

## Requirement-by-requirement result

| Requirement | Determination | Current authoritative evidence |
| --- | --- | --- |
| Preserve and formally close the experimental Phase 1 record | Complete | Fixed annotated baseline, historical workbench, and read-only product boundary in the [operating manual](README.md) and [public workbench](../../public-history/index.html) |
| Provide Phase 2 and Phase 3 workbench/governance structure | Complete | Phase operating manual, workbench tabs, exit gate, recommendation register, specialist plan, and roadmap |
| Critically assess architecture, structure, persistence, performance, security/privacy, clinical safety, UI/accessibility, operations, contracts, and supply chain | Substantially complete at the available engineering-evidence level; applicable rows remain In review | [Coverage matrix](coverage-matrix.md), ten assessment packets, residual/runtime reconciliation, [scorecard](scorecard.md), and canonical register |
| Analyze the C# data-access/EF Core and parameterized-SQL boundary without assuming a blanket ORM rewrite | Complete | [External-feedback Packet 2](external-feedback/ext-s001-packet-2-ef-core-sql-fitness.md), `P2-04-*` findings, and `P2-R004` preserve a measured EF/SQL hybrid boundary |
| Incorporate useful Reddit/public criticism without profiling commenters or treating comments as facts | Complete | [External-feedback challenge process](external-feedback/README.md) and three source-linked, independently verified challenge packets |
| Record finding severity, counterevidence, independent verification, uncertainty, and human validation needs | Complete | [Finding register](findings/README.md): 64 validated findings, including 39 High production-target blockers; linked assessment packets preserve counterevidence and limits |
| Exercise synthetic runtime, migration/recovery, build, browser, FHIR, laboratory, authorization, and deployment-readiness evidence where available | Complete at the available evidence level | [Runtime-readiness packet](assessments/cov-014-019-runtime-readiness.md); both passing exercises and failed/short-circuited gates are retained rather than hidden |
| Fix target scope and production-worthiness defaults | Complete | `P2-D014` and `P2-D016` in the [decision log](decision-log.md): modern UI only; FHIR R4/SMART; synthetic external laboratory API; facility/purpose authorization; vendor-neutral SSO/test IdP; gates remain open |
| Turn findings into ordered, scoped, measurable Phase 3 recommendations | Complete | Seven [decision-ready recommendation packets](recommendations/README.md), each with alternatives, dependencies, scope, rollback, acceptance criteria, bounded change packets, and a pending decision record |
| Define specialist validation and delivery sequencing | Complete | [Specialist validation plan](specialist-validation-plan.md) and [Phase 3 roadmap](phase-3-roadmap.md) |
| Keep product, schema, infrastructure, tests, and runtime implementation unchanged during Phase 2 | Complete | Product-scope diff from the fixed baseline is empty for `avenchart`, `avenchart-ui`, `infra`, and `.github`; Phase 2 edits are governance/evidence/workbench documentation only |

## Gate evidence that cannot be inferred or completed by documentation

The following remains intentionally open, not missing from this audit:

1. **Specialist decisions and delivered acceptance evidence.** Clinical, HIM, privacy/security, laboratory/FHIR, pharmacy, scheduling, accessibility, data-operations, release, and deployment roles must review the packet-specific behavior. The exact assignments and evidence are listed in the [specialist validation plan](specialist-validation-plan.md).
2. **Recommendation acceptance and accountable delivery ownership.** The target policies are approved, but none of `P2-R001` through `P2-R007` has been accepted as an implementation packet or assigned named implementation, operations, and rollback owners.
3. **Current-environment proof.** A healthy older Azure demo and local synthetic runtime do not prove the current baseline's deployment topology, restore/failover, alerting, performance, external-provider configuration, or release provenance.
4. **Explicit program-owner authorization.** The user directed that gates remain open until explicit closure instructions. This audit does not reinterpret the approved defaults as such authorization.

These are not defects in the audit process. They are the intentionally preserved boundary between Phase 2 diagnosis/planning and Phase 3 product change.

## First authorized work when the gate is directed to open

The dependency-safe starting point is Wave 0 of the [roadmap](phase-3-roadmap.md): `R007-A` verification manifest, `R004-A` schema-authority/bootstrap decision, `R006-A` API/OpenAPI/FHIR contract design, and the relevant specialist rule matrices. Wave 1 may begin only after those packets are accepted and establishes identity/resource safety before broad clinical or interoperability changes.

## Verification performed for this audit

- Seven recommendation packets contain every section required by `recommendation-template.md`.
- All local Markdown links beneath `docs/phase-2` resolve.
- The public workbench has no duplicate HTML IDs.
- `git diff --name-only phase-1-experimental -- avenchart avenchart-ui infra .github` is empty.

## Final handoff

Phase 2 has completed the work it can perform without altering the fixed product or substituting engineering judgment for accountable human approval. The next action is an explicit Phase 3 authorization decision for one or more Wave 0 packets, with named owners and the linked specialist review—not a further exploratory code change.
